Anthrax lethal toxin and the induction of CD4 T cell immunity

Toxins

Volumn 4, Issue 10, 2012, Pages 878-899

  Ascough, Stephanie ^a   Ingram, Rebecca J ^b   Altmann, Daniel M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Anthrax; CD4 T cell; Epitope; Lethal factor; Protective antigen; Vaccine

Indexed keywords

ANTHRAX TOXIN; CARRIER PROTEINS AND BINDING PROTEINS; CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN NLRP1B; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BACILLUS ANTHRACIS; BACTERIAL SURVIVAL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME STRUCTURE; INTERFERON PRODUCTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNITY; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

BACILLUS ANTHRACIS;

EID: 84868345656     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4100878     Document Type: Review

References (142)

1. Baillie, L.W., Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol. 2006, 101, 594-606.
2. Shlyakhov, E.N.; Rubinstein, E. Human live anthrax vaccine in the former USSR. Vaccine 1994, 12, 727-730.
3. Baillie, L.W.; Fowler, K.; Turnbull, P.C. Human immune responses to the UK human anthrax vaccine. J. Appl. Microbiol. 1999, 87, 306-308.
4. Turnbull, P.C. Anthrax vaccines: Past, present and future. Vaccine 1991, 9, 533-539.
5. Shlyakhov, E.; Rubinstein, E.; Novikov, I. Anthrax post-vaccinal cell-mediated immunity in humans: Kinetics pattern. Vaccine 1997, 15, 631-636.
6. Splino, M.; Patocka, J.; Prymula, R.; Chlibek, R. Anthrax vaccines. Ann. Saudi. Med. 2005, 25, 143-149.
7. Leppla, S.H.; Robbins, J.B.; Schneerson, R.; Shiloach, J. Development of an improved vaccine for anthrax. J. Clin. Invest. 2002, 110, 141-144.
8. Brey, R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 2005, 57, 1266-1292.
9. Baillie, L. The development of new vaccines against Bacillus anthracis. J. Appl. Microbiol. 2001, 91, 609-613.
10. Enstone, J.E.; Wale, M.C.; Nguyen-Van-Tam, J.S.; Pearson, J.C. Adverse medical events in British service personnel following anthrax vaccination. Vaccine 2003, 21, 1348-1354.
11. Brown, B.K.; Cox, J.; Gillis, A.; VanCott, T.C.; Marovich, M.; Milazzo, M.; Antonille, T.S.; Wieczorek, L.; McKee, K.T., Jr.; Metcalfe, K.; et al. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS One 2010, 5, e13849.
12. Campbell, J.D.; Clement, K.H.; Wasserman, S.S.; Donegan, S.; Chrisley, L.; Kotloff, K.L., Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum. Vaccin. 2007, 3, 205-211.
13. Gorse, G.J.; Keitel, W.; Keyserling, H.; Taylor, D.N.; Lock, M.; Alves, K.; Kenner, J.; Deans, L.; Gurwith, M. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine 2006, 24, 5950-5959.
14. Williamson, E.D.; Hodgson, I.; Walker, N.J.; Topping, A.W.; Duchars, M.G.; Mott, J.M.; Estep, J.; Lebutt, C.; Flick-Smith, H.C.; Jones, H.E.; et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 2005, 73, 5978-5987.
15. Garmory, H.S.; Titball, R.W.; Griffin, K.F.; Hahn, U.; Bohm, R.; Beyer, W. Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect. Immun. 2003, 71, 3831-3836.
16. Langley, W.A.; Bradley, K.C.; Li, Z.N.; Smith, M.E.; Schnell, M.J.; Steinhauer, D.A. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: Implications for disparate immune system priming pathways. J. Virol. 2010, 84, 8300-8307.
17. Galloway, D.R.; Baillie, L. DNA vaccines against anthrax. Expert. Opin. Biol. Ther. 2004, 4, 1661-1667.
18. Phipps, A.J.; Premanandan, C.; Barnewall, R.E.; Lairmore, M.D. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol. Mol. Biol. Rev. 2004, 68, 617-629.
19. Beedham, R.J.; Turnbull, P.C.; Williamson, E.D. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001, 19, 4409-4416.
20. Staats, H.F.; Alam, S.M.; Scearce, R.M.; Kirwan, S.M.; Zhang, J.X.; Gwinn, W.M.; Haynes, B.F. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 2007, 75, 5443-5452.
21. Pitt, M.L.; Little, S.F.; Ivins, B.E.; Fellows, P.; Barth, J.; Hewetson, J.; Gibbs, P.; Dertzbaugh, M.; Friedlander, A.M. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001, 19, 4768-4773.
22. Little, S.F.; Webster, W.M.; Ivins, B.E.; Fellows, P.F.; Norris, S.L.; Andrews, G.P. Development of an in vitro-based potency assay for anthrax vaccine. Vaccine 2004, 22, 2843-2852.
23. Little, S.F.; Ivins, B.E.; Fellows, P.F.; Friedlander, A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 1997, 65, 5171-5175.
24. McBride, B.W.; Mogg, A.; Telfer, J.L.; Lever, M.S.; Miller, J.; Turnbull, P.C.; Baillie, L. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998, 16, 810-817.
25. Reuveny, S.; White, M.D.; Adar, Y.Y.; Kafri, Y.; Altboum, Z.; Gozes, Y.; Kobiler, D.; Shafferman, A.; Velan, B. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 2001, 69, 2888-2893.
26. Weiss, S.; Kobiler, D.; Levy, H.; Marcus, H.; Pass, A.; Rothschild, N.; Altboum, Z. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 2006, 74, 394-398.
27. Pitt, M.L.; Little, S.; Ivins, B.E.; Fellows, P.; Boles, J.; Barth, J.; Hewetson, J.; Friedlander, A.M. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 1999, 87, 304.
28. Fellows, P.F.; Linscott, M.K.; Ivins, B.E.; Pitt, M.L.; Rossi, C.A.; Gibbs, P.H.; Friedlander, A.M. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001, 19, 3241-3247.
29. Turnbull, P.C.; Broster, M.G.; Carman, J.A.; Manchee, R.J.; Melling, J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 1986, 52, 356-363.
30. Baillie, L.W.; Huwar, T.B.; Moore, S.; Mellado-Sanchez, G.; Rodriguez, L.; Neeson, B.N.; Flick-Smith, H.C.; Jenner, D.C.; Atkins, H.S.; Ingram, R.J.; et al. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 2010, 28, 6740-6748.
31. Turnbull, P.C.; Leppla, S.H.; Broster, M.G.; Quinn, C.P.; Melling, J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. 1988, 177, 293-303.
32. Van den Enden, E.; Van Gompel, A.; Van Esbroeck, M. Cutaneous anthrax, Belgian traveler. Emerg. Infect. Dis. 2006, 12, 523-525.
33. Brenneman, K.E.; Doganay, M.; Akmal, A.; Goldman, S.; Galloway, D.R.; Mateczun, A.J.; Cross, A.S.; Baillie, L.W. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax. FEMS Immunol. Med. Microbiol. 2011, 62, 164-172.
34. Little, S.F.; Ivins, B.E.; Webster, W.M.; Fellows, P.F.; Pitt, M.L.; Norris, S.L.; Andrews, G.P. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 2006, 24, 2530-2536.
35. Crowe, S.R.; Ash, L.L.; Engler, R.J.; Ballard, J.D.; Harley, J.B.; Farris, A.D.; James, J.A. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J. Infect. Dis. 2010, 202, 251-260.
36. Crowe, S.R.; Garman, L.; Engler, R.J.; Farris, A.D.; Ballard, J.D.; Harley, J.B.; James, J.A. Anthrax vaccination induced anti-lethal factor IgG: Fine specificity and neutralizing capacity. Vaccine 2011, 29, 3670-3678.
37. Smith, K.; Crowe, S.R.; Garman, L.; Guthridge, C.J.; Muther, J.J.; McKee, E.; Zheng, N.Y.; Farris, A.D.; Guthridge, J.M.; Wilson, P.C.; et al. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine 2012, 30, 4276-4283.
38. Hewetson, J.F.; Little, S.F.; Ivins, B.E.; Johnson, W.M.; Pittman, P.R.; Brown, J.E.; Norris, S.L.; Nielsen, C.J. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 2008, 26, 4262-4266.
39. Lim, N.K.; Kim, J.H.; Oh, M.S.; Lee, S.; Kim, S.Y.; Kim, K.S.; Kang, H.J.; Hong, H.J.; Inn, K.S. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. 2005, 73, 6547-6551.
40. Nguyen, M.L.; Terzyan, S.; Ballard, J.D.; James, J.A.; Farris, A.D. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect. Immun. 2009, 77, 4714-4723.
41. Nguyen, M.L.; Crowe, S.R.; Kurella, S.; Teryzan, S.; Cao, B.; Ballard, J.D.; James, J.A.; Farris, A.D. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect. Immun. 2009, 77, 162-169.
42. Price, B.M.; Liner, A.L.; Park, S.; Leppla, S.H.; Mateczun, A.; Galloway, D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 2001, 69, 4509-4515.
43. Pezard, C.; Weber, M.; Sirard, J.C.; Berche, P.; Mock, M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 1995, 63, 1369-1372.
44. Hermanson, G.; Whitlow, V.; Parker, S.; Tonsky, K.; Rusalov, D.; Ferrari, M.; Lalor, P.; Komai, M.; Mere, R.; Bell, M.; et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. USA 2004, 101, 13601-13606.
45. Kwok, W.W.; Tan, V.; Gillette, L.; Littell, C.T.; Soltis, M.A.; LaFond, R.B.; Yang, J.; James, E.A.; DeLong, J.H. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J. Immunol. 2012, 188, 2537-2544.
46. Kwok, W.W.; Yang, J.; James, E.; Bui, J.; Huston, L.; Wiesen, A.R.; Roti, M. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells. Infect. Immun. 2008, 76, 4538-4545.
47. Laughlin, E.M.; Miller, J.D.; James, E.; Fillos, D.; Ibegbu, C.C.; Mittler, R.S.; Akondy, R.; Kwok, W.; Ahmed, R.; Nepom, G. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine. Infect. Immun. 2007, 75, 1852-1860.
48. Glomski, I.J.; Cone, J.P.; Mock, M.; Goossens, P.L. Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J. Immunol. 2007, 178, 2646-2650.
49. Ingram, R.J.; Metan, G.; Maillere, B.; Doganay, M.; Ozkul, Y.; Kim, L.U.; Baillie, L.; Dyson, H.; Williamson, E.D.; Chu, K.K.; et al. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J. Immunol. 2010, 184, 3814-3821.
50. Wattiau, P.; Govaerts, M.; Frangoulidis, D.; Fretin, D.; Kissling, E.; Van, H.M.; China, B.; Poncin, M.; Pirenne, Y.; Hanquet, G. Immunologic response of unvaccinated workers exposed to anthrax, Belgium. Emerg. Infect. Dis. 2009, 15, 1637-1640.
51. Doolan, D.L.; Freilich, D.A.; Brice, G.T.; Burgess, T.H.; Berzins, M.P.; Bull, R.L.; Graber, N.L.; Dabbs, J.L.; Shatney, L.L.; Blazes, D.L.; et al. The US capitol bioterrorism anthrax exposures: Clinical epidemiological and immunological characteristics. J. Infect. Dis. 2007, 195, 174-184.
52. Gilbert, S.C. T-cell-inducing vaccines-What's the future. Immunology 2012, 135, 19-26.
53. Petosa, C.; Collier, R.J.; Klimpel, K.R.; Leppla, S.H.; Liddington, R.C. Crystal structure of the anthrax toxin protective antigen. Nature 1997, 385, 833-838.
54. Scobie, H.M.; Rainey, G.J.; Bradley, K.A.; Young, J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 5170-5174.
55. Bradley, K.A.; Mogridge, J.; Mourez, M.; Collier, R.J.; Young, J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414, 225-229.
56. Scobie, H.M.; Wigelsworth, D.J.; Marlett, J.M.; Thomas, D.; Rainey, G.J.; Lacy, D.B.; Manchester, M.; Collier, R.J.; Young, J.A. Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog. 2006, 2, e111.
57. Bradley, K.A.; Mogridge, J.; Jonah, G.; Rainey, A.; Batty, S.; Young, J.A. Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. J. Biol. Chem. 2003, 278, 49342-49347.
58. Averette, K.M.; Pratt, M.R.; Yang, Y.; Bassilian, S.; Whitelegge, J.P.; Loo, J.A.; Muir, T.W.; Bradley, K.A. Anthrax lethal toxin induced lysosomal membrane permeabilization and cytosolic cathepsin release is Nlrplb/Nalplb-dependent. PLoS One 2009, 4, e7913.
59. Martchenko, M.; Jeong, S.Y.; Cohen, S.N. Heterodimeric integrin complexes containing beta 1-integrin promote internalization and lethality of anthrax toxin. Proc. Natl. Acad. Sci. USA 2010, 107, 15583-15588.
60. Scobie, H.M.; Thomas, D.; Marlett, J.M.; Destito, G.; Wigelsworth, D.J.; Collier, R.J.; Young, J.A.; Manchester, M. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J. Infect. Dis. 2005, 192, 1047-1051.
61. Liu, S.; Crown, D.; Miller-Randolph, S.; Moayeri, M.; Wang, H.; Hu, H.; Morley, T.; Leppla, S.H. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc. Natl. Acad. Sci. USA 2009, 106, 12424-12429.
62. Hu, H.; Leppla, S.H. Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein. PLoS One 2009, 4, e7946.
63. Pannifer, A.D.; Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J.; Lacy, D.B.; Collier, R.J.; Park, S.; Leppla, S.H.; Hanna, P.; Liddington, R.C. Crystal structure of the anthrax lethal factor. Nature 2001, 414, 229-233.
64. Duesbery, N.S.; Vande Woude, G.F. Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase. J. Appl. Microbiol. 1999, 87, 289-293.
65. Bragg, T.S.; Robertson, D.L. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene 1989, 81, 45-54.
66. Lacy, D.B.; Mourez, M.; Fouassier, A.; Collier, R.J. Mapping the anthrax protective antigen binding site on the lethal and edema factors. J. Biol. Chem. 2002, 277, 3006-3010.
67. Arora, N.; Leppla, S.H. Residues-1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 1993, 268, 3334-3341.
68. Liao, Q.; Strong, A.J.; Liu, Y.; Liu, Y.; Meng, P.; Fu, Y.; Touzjian, N.; Shao, Y.; Zhao, Z.; Lu, Y. HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques. Vaccine 2012, 30, 1601-1608.
69. Ascenzi, P.; Visca, P.; Ippolito, G.; Spallarossa, A.; Bolognesi, M.; Montecucco, C. Anthrax toxin: A tripartite lethal combination. FEBS Lett. 2002, 531, 384-388.
70. Quinn, C.P.; Singh, Y.; Klimpel, K.R.; Leppla, S.H. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J. Biol. Chem. 1991, 266, 20124-20130.
71. Liang, X.D.; Young, J.J.; Boone, S.A.; Waugh, D.S.; Duesbery, N.S. Involvement of domain II in toxicity of anthrax lethal factor. J. Biol. Chem. 2004, 279, 52473-52478.
72. Klimpel, K.R.; Arora, N.; Leppla, S.H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 1994, 13, 1093-1100.
73. Hammond, S.E.; Hanna, P.C. Lethal factor active-site mutations affect catalytic activity in vitro. Infect. Immun. 1998, 66, 2374-2378.
74. Tonello, F.; Naletto, L.; Romanello, V.; Dal, M.F.; Montecucco, C. Tyrosine-728 and glutamic acid-735 are essential for the metalloproteolytic activity of the lethal factor of Bacillus anthracis. Biochem. Biophys. Res. Commun. 2004, 313, 496-502.
75. Rossetto, O.; Caccin, P.; Rigoni, M.; Tonello, F.; Bortoletto, N.; Stevens, R.C.; Montecucco, C. Active-site mutagenesis of tetanus neurotoxin implicates TYR-375 and GLU-271 in metalloproteolytic activity. Toxicon 2001, 39, 1151-1159.
76. Rigoni, M.; Caccin, P.; Johnson, E.A.; Montecucco, C.; Rossetto, O. Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A. Biochem. Biophys. Res. Commun. 2001, 288, 1231-1237.
77. Duesbery, N.S.; Webb, C.P.; Leppla, S.H.; Gordon, V.M.; Klimpel, K.R.; Copeland, T.D.; Ahn, N.G.; Oskarsson, M.K.; Fukasawa, K.; Paull, K.D.; Vande Woude, G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737.
78. Liu, Y.S.; Shepherd, E.G.; Nelin, L.D. MAPK phosphatases-regulating the immune response. Nat. Rev. Immun. 2007, 7, 202-212.
79. Lange-Carter, C.A.; Pleiman, C.M.; Gardner, A.M.; Blumer, K.J.; Johnson, G.L. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 1993, 260, 315-319.
80. Hagemann, C.; Blank, J.L. The ups and downs of MEK kinase interactions. Cell Signal. 2001, 13, 863-875.
81. Gerwins, P.; Blank, J.L.; Johnson, G.L. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. J. Biol. Chem. 1997, 272, 8288-8295.
82. Salmeron, A.; Ahmad, T.B.; Carlile, G.W.; Pappin, D.; Narsimhan, R.P.; Ley, S.C. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 1996, 15, 817-826.
83. Ichijo, H.; Nishida, E.; Irie, K.; Ten, D.P.; Saitoh, M.; Moriguchi, T.; Takagi, M.; Matsumoto, K.; Miyazono, K.; Gotoh, Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275, 90-94.
84. Yamaguchi, K.; Shirakabe, K.; Shibuya, H.; Irie, K.; Oishi, I.; Ueno, N.; Taniguchi, T.; Nishida, E.; Matsumoto, K. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270, 2008-2011.
85. Roux, P.P.; Blenis, J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 2004, 68, 320-344.
86. Turk, B.E. Manipulation of host signalling pathways by anthrax toxins. Biochem. J. 2007, 402, 405-417.
87. Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 2000, 352 (Pt. 3), 739-745.
88. Chopra, A.P.; Boone, S.A.; Liang, X.D.; Duesbery, N.S. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J. Biol. Chem. 2003, 278, 9402-9406.
89. Bardwell, A.J.; Abdollahi, M.; Bardwell, L. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. Biochem. J. 2004, 378, 569-577.
90. Seyfried, J.; Wang, X.; Kharebava, G.; Tournier, C. A novel mitogen-activated protein kinase docking site in the N terminus of MEK5alpha organizes the components of the extracellular signal-regulated kinase 5 signaling pathway. Mol. Cell Biol. 2005, 25, 9820-9828.
91. Friedlander, A.M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 1986, 261, 7123-7126.
92. Agrawal, A.; Lingappa, J.; Leppla, S.H.; Agrawal, S.; Jabbar, A.; Quinn, C.; Pulendran, B. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 2003, 424, 329-334.
93. Welkos, S.L.; Friedlander, A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 1988, 4, 53-69.
94. Welkos, S.L.; Keener, T.J.; Gibbs, P.H. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 1986, 51, 795-800.
95. Jones, W.I., Jr.; Klein, F.; Walker, J.S.; Mahlandt, B.G.; Dobbs, J.P.; Lincoln, R.E. In vivo growth and distribution of anthrax bacilli in resistant, susceptible, and immunized hosts. J. Bacteriol. 1967, 94, 600-608.
96. Beall, F.A.; Dalldorf, F.G. The pathogenesis of the lethal effect of anthrax toxin in the rat. J. Infect. Dis. 1966, 116, 377-389.
97. Kim, S.O.; Jing, Q.; Hoebe, K.; Beutler, B.; Duesbery, N.S.; Han, J.H. Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha. J Biol. Chem. 2003, 278, 7413-7421.
98. Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett. 1999, 462, 199-204.
99. Watters, J.W.; Dietrich, W.F. Genetic, physical, and transcript map of the Ltxsl region of mouse chromosome 11. Genomics 2001, 73, 223-231.
100. Roberts, J.E.; Watters, J.W.; Ballard, J.D.; Dietrich, W.F. Ltxl, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11. Mol. Microbiol. 1998, 29, 581-591.
101. Boyden, E.D.; Dietrich, W.F. Nalplb controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 2006, 38, 240-244.
102. Terra, J.K.; Cote, C.K.; France, B.; Jenkins, A.L.; Bozue, J.A.; Welkos, S.L.; LeVine, S.M.; Bradley, K.A. Cutting edge: Resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp l b/Nlrp l b. J Immunol. 2010, 184, 17-20.
103. Moayeri, M.; Crown, D.; Newman, Z.L.; Okugawa, S.; Eckhaus, M.; Cataisson, C.; Liu, S.; Sastalla, I.; Leppla, S.H. Inflammasome sensor Nlrplb-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog. 2010, 6, e1001222.
104. Terra, J.K.; France, B.; Cote, C.K.; Jenkins, A.; Bozue, J.A.; Welkos, S.L.; Bhargava, R.; Ho, C.L.; Mehrabian, M.; Pan, C.; et al. Allelic variation on murine chromosome 11 modifies host inflammatory responses and resistance to Bacillus anthracis. PLoS Pathog. 2011, 7, e1002469.
105. Kang, T.J.; Basu, S.; Zhang, L.; Thomas, K.E.; Vogel, S.N.; Baillie, L.; Cross, A.S. Bacillus anthracis spores and lethal toxin induce IL-lbeta via functionally distinct signaling pathways. Eur. J. Immun. 2008, 38, 1574-1584.
106. McAllister, R.D.; Singh, Y.; du Bois, W.D.; Potter, M.; Boehm, T.; Meeker, N.D.; Fillmore, P.D.; Anderson, L.M.; Poynter, M.E.; Teuscher, C. Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci. Am. J. Pathol. 2003, 163, 1735-1741.
107. Henry, T.; Brotcke, A.; Weiss, D.S.; Thompson, L.J.; Monack, D.M. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J. Exp. Med. 2007, 204, 987-994.
108. Moayeri, M.; Haines, D.; Young, H.A.; Leppla, S.H. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 2003, 112, 670-682.
109. Levinsohn, J.L.; Newman, Z.L.; Hellmich, K.A.; Fattah, R.; Getz, M.A.; Liu, S.; Sastalla, I.; Leppla, S.H.; Moayeri, M. Anthrax lethal factor cleavage of nlrp 1 is required for activation of the inflammasome. PLoS Pathog. 2012, 8, e1002638.
110. Newman, Z.L.; Printz, M.P.; Liu, S.; Crown, D.; Breen, L.; Miller-Randolph, S.; Flodman, P.; Leppla, S.H.; Moayeri, M. Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp l. PLoS Pathog. 2010, 6, e1000906.
111. Newman, Z.L.; Crown, D.; Leppla, S.H.; Moayeri, M. Anthrax lethal toxin activates the inflammasome in sensitive rat macrophages. Biochem. Biophys. Res. Commun. 2010, 398, 785-789.
112. Broz, P.; von, M.J.; Jones, J.W.; Vance, R.E.; Monack, D.M. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host. Microb. 2010, 8, 471-483.
113. Quinn, C.P.; Dull, P.M.; Semenova, V.; Li, H.; Crotty, S.; Taylor, T.H.; Steward-Clark, E.; Stamey, K.L.; Schmidt, D.S.; Stinson, K.W.; et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis. 2004, 190, 1228-1236.
114. Ingram, R.; Ascough, S.; Kim, L.U.; Metan, G.; Doganay, M.; Baillie, L.; Williamson, E.D.; Robinson, J.H.; Maillere, B.; Sriskandan, S.; et al. Natural cutaneous anthrax infection in humans induces a long-lasting Thl, Th2, Th9 and Th17 response. 2012, to be submitted for publication.
115. Wickliffe, K.E.; Leppla, S.H.; Moayeri, M. Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome. Cell Microbiol. 2008, 10, 332-343.
116. Hanna, P.C.; Kochi, S.; Collier, R.J. Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol. Biol. Cell 1992, 3, 1269-1277.
117. Paccani, S.R.; Tonello, F.; Ghittoni, R.; Natale, M.; Muraro, L.; D'Elios, M.M.; Tang, W.J.; Montecucco, C.; Baldari, C.T. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. 2005, 201, 325-331.
118. Comer, J.E.; Chopra, A.K.; Peterson, J.W.; Konig, R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect. Immun. 2005, 73, 8275-8281.
119. Fang, H.; Cordoba-Rodriguez, R.; Lankford, C.S.R.; Frucht, D.M. Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4(+) T cells. J. Immun. 2005, 174, 4966-4971.
120. Paccani, S.R.; Tonello, F.; Patrussi, L.; Capitani, N.; Simonato, M.; Montecucco, C.; Baldari, C.T. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microbiol. 2007, 9, 924-929.
121. Huang, C.; Jacobson, K.; Schaller, M.D. MAP kinases and cell migration. J. Cell Sci. 2004, 117, 4619-4628.
122. Howe, A.K. Regulation of actin-based cell migration by cAMP/PKA. Biochim. Biophys. Acta 2004, 1692, 159-174.
123. Paccani, S.R.; Benagiano, M.; Capitani, N.; Zornetta, I.; Ladant, D.; Montecucco, C.; D'Elios, M.M.; Baldari, C.T. The adenylate cyclase toxins of bacillus anthracis and bordetella pertussis promote Th2 cell development by shaping T cell antigen receptor signaling. Plos Pathog. 2009, 5, e1000325.
124. Boyaka, P.N.; Tafaro, A.; Fischer, R.; Leppla, S.H.; Fujihashi, K.; McGhee, J.R. Effective mucosal immunity to anthrax: Neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 2003, 170, 5636-5643.
125. Grun, J.L.; Maurer, P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 1989, 121, 134-145.
126. Marinaro, M.; Staats, H.F.; Hiroi, T.; Jackson, R.J.; Coste, M.; Boyaka, P.N.; Okahashi, N.; Yamamoto, M.; Kiyono, H.; Bluethmann, H.; Fujihashi, K.; McGhee, J.R. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 1995, 155, 4621-4629.
127. Yamamoto, S.; Kiyono, H.; Yamamoto, M.; Imaoka, K.; Fujihashi, K.; van Ginkel, F.W.; Noda, M.; Takeda, Y.; McGhee, J.R. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 1997, 94, 5267-5272.
128. Gold, J.A.; Hoshino, Y.; Hoshino, S.; Jones, M.B.; Nolan, A.; Weiden, M.D. Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis. Infect. Immun. 2004, 72, 1291-1297.
129. Gonzales, C.M.; Williams, C.B.; Calderon, V.E.; Huante, M.B.; Moen, S.T.; Popov, V.L.; Baze, W.B.; Peterson, J.W.; Endsley, J.J. Antibacterial role for natural killer cells in host defense to Bacillus anthracis. Infect. Immun. 2012, 80, 234-242.
130. Klezovich-Benard, M.; Corre, J.P.; Jusforgues-Saklani, H.; Fiole, D.; Burjek, N.; Tournier, J.N.; Goossens, P.L. Mechanisms of NK cell-macrophage Bacillus anthracis crosstalk: A balance between stimulation by spores and differential disruption by toxins. PLoS Pathog. 2012, 8, e1002481.
131. Devera, T.S.; Aye, L.M.; Lang, G.A.; Joshi, S.K.; Ballard, J.D.; Lang, M.L. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infect. Immun. 2010, 78, 1610-1617.
132. Devera, T.S.; Joshi, S.K.; Aye, L.M.; Lang, G.A.; Ballard, J.D.; Lang, M.L. Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNgamma. PLoS One 2011, 6, e23817.
133. Abboud, N.; Chow, S.K.; Saylor, C.; Janda, A.; Ravetch, J.V.; Scharff, M.D.; Casadevall, A. A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 2010, 207, 2395-2405.
134. Joshi, S.K.; Lang, G.A.; Larabee, J.L.; Devera, T.S.; Aye, L.M.; Shah, H.B.; Ballard, J.D.; Lang, M.L. Bacillus anthracis lethal toxin disrupts TCR signaling in CD 1d-restricted NKT cells leading to functional anergy. PLoSPathog. 2009, 5, e1000588.
135. Khan, M.A.; Gallo, R.M.; Brutkiewicz, R.R. Anthrax lethal toxin impairs CD 1 d-mediated antigen presentation by targeting the ERK1/2 MAPK pathway. Infect. Immun. 2010, 78, 1859-1863.
136. Paccani, S.R.; Benagiano, M.; Savino, M.T.; Finetti, F.; Tonello, F.; D'Elios, M.M.; Baldari, C.T. The adenylate cyclase toxin of Bacillus anthracis is a potent promoter of T(H)17 cell development. J. Allergy Clin. Immunol. 2011, 127, 1635-1637.
137. Allen, J.S.; Skowera, A.; Rubin, G.J.; Wessely, S.; Peakman, M. Long-lasting T cell responses to biological warfare Vaccines in human vaccinees. Clin. Infect. Dis. 2006, 43,1-7.
138. Martchenko, M.; Candille, S.I.; Tang, H.; Cohen, S.N. Human genetic variation altering anthrax toxin sensitivity. Proc. Natl. Acad. Sci. USA 2012, 109, 2972-2977.
139. Marano, N.; Plikaytis, B.D.; Martin, S.W.; Rose, C.; Semenova, V.A.; Martin, S.K.; Freeman, A.E.; Li, H.; Mulligan, M.J.; Parker,S.D.; et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: A randomized trial. J. Am. Med. Assoc. 2008, 300, 1532-1543.
140. Ingram, R.; Baillie, L. It's in the genes! Human genetic diversity and the response to anthrax vaccines. Expert Rev. Vaccin 2012, 11, 633-635.
141. Fish, D.C.; Mahlandt, B.G.; Dobbs, J.P.; Lincoln, R.E. Purification and properties of in vitro-produced anthrax toxin components. J Bacteriol. 1968, 95, 907-918.
142. Mock, M.; Roques, B.P. Progress in rapid screening of bacillus anthracis lethal factor activity. Proc. Natl. Acad. Sci. USA 2002, 99, 6527-6529.